High expression of interleukin‑enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma

Xu,Zhangyan; Huang,Hua; Li,Xing; Ji,Cheng; Liu,Yifei; Liu,Xiaojuan; Zhu,Jun; Wang,Zhendong; Zhang,Haijian; Shi,Jiahai

doi:10.3892/ol.2020.11330

High expression of interleukin‑enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma

Authors:
- Zhangyan Xu
- Hua Huang
- Xing Li
- Cheng Ji
- Yifei Liu
- Xiaojuan Liu
- Jun Zhu
- Zhendong Wang
- Haijian Zhang
- Jiahai Shi
View Affiliations

Affiliations: Nantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Pathogen Biology, Medical College, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: January 22, 2020 https://doi.org/10.3892/ol.2020.11330
Pages: 2141-2152
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin‑enhancer binding factor 3 (ILF3) is a double‑stranded RNA‑binding protein that has been reported to contribute to the occurrence and progression of various malignant tumors. The aim of the present study was to evaluate the prognostic value of ILF3 and to apply this knowledge to avoid excessive medical treatment in patients with lung adenocarcinoma (LUAD). ILF3 expression in a discovery set consisting of tumor and peri‑tumor tissue microarrays was analyzed using immunohistochemical methods. The mRNA level of ILF3 was subsequently analyzed in a validation set downloaded from The Cancer Genome Atlas. The Kaplan‑Meier method, univariate and multivariate Cox analyses, decision curve analysis and nomogram models were used to evaluate the prognostic value of ILF3. ILF3 expression was upregulated in tumor tissues compared with peri‑tumor tissues and was negatively associated with the overall survival time of patients with LUAD in the discovery and validation sets. Moreover, ILF3 expression was used for risk stratification in patients with tumor‑node‑metastasis stages II‑IV and poor‑to‑moderate tumor differentiation. ILF3 expression was identified as an independent predictor of adverse prognosis for patients with LUAD in the discovery and validation sets. Finally, nomogram models for the 3‑ and 5 year survival time of patients with LUAD revealed that ILF3 expression may be used to improve the predictive accuracy of the prognosis and to avoid excessive medical treatment for certain patients with the disease. Overall, the data obtained in the current study revealed that high ILF3 expression was associated with poor prognosis, and demonstrated that ILF3, as a potential independent risk factor, may improve the hierarchical postoperative management of patients with LUAD.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-Small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Yao S, Zhong L, Liu J, Feng J, Bian T, Zhang Q, Chen J, Lv X, Chen J and Liu Y: Prognostic value of decreased GRK6 expression in lung adenocarcinoma. J Cancer Res Clin Oncol. 142:2541–2549. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chang JT, Lee YM and Huang RS: The impact of the cancer genome atlas on lung cancer. Transl Res. 166:568–585. 2015. View Article : Google Scholar : PubMed/NCBI
6	Minguet J, Smith KH and Bramlage P: Targeted therapies for treatment of non-small cell lung cancer-recent advances and future perspectives. Int J Cancer. 138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
7	Castella S, Bernard R, Corno M, Fradin A and Larcher JC: Ilf3 and NF90 functions in RNA biology. Wiley Interdiscip Rev RNA. 6:243–256. 2015. View Article : Google Scholar : PubMed/NCBI
8	Xu YH, Leonova T and Grabowski GA: Cell cycle dependent intracellular distribution of two spliced isoforms of TCP/ILF3 proteins. Mol Genet Metab. 80:426–436. 2003. View Article : Google Scholar : PubMed/NCBI
9	Zhuang J, Shen L, Yang L, Huang X, Lu Q, Cui Y, Zheng X, Zhao X, Zhang D, Huang R, et al: TGFβ1 promotes gemcitabine resistance through regulating the LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. Theranostics. 7:3053–3067. 2017. View Article : Google Scholar : PubMed/NCBI
10	Larcher JC, Gasmi L, Viranaicken W, Edde B, Bernard R, Ginzburg I and Denoulet P: Ilf3 and NF90 associate with the axonal targeting element of tau mRNA. FASEB J. 18:1761–1763. 2004. View Article : Google Scholar : PubMed/NCBI
11	Pei Y, Zhu P, Dang Y, Wu J, Yang X, Wan B, Liu JO, Yi Q and Yu L: Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation. J Immunol. 180:222–229. 2008. View Article : Google Scholar : PubMed/NCBI
12	Shi L, Zhao G, Qiu D, Godfrey WR, Vogel H, Rando TA, Hu H and Kao PN: NF90 regulates cell cycle exit and terminal myogenic differentiation by direct binding to the 3′-untranslated region of MyoD and p21WAF1/CIP1 mRNAs. J Biol Chem. 280:18981–18989. 2005. View Article : Google Scholar : PubMed/NCBI
13	Li X, Liu CX, Xue W, Zhang Y, Jiang S, Yin QF, Wei J, Yao RW, Yang L and Chen LL: Coordinated circRNA biogenesis and function with NF90/NF110 in viral infection. Mol Cell. 67:214–227. 2017. View Article : Google Scholar : PubMed/NCBI
14	Hu Q, Lu YY, Noh H, Hong S, Dong Z, Ding HF, Su SB and Huang S: Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene. 32:3933–3943. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Yang C, Zhang M, Liu H, Gong C, Zhang J, Xu S, Zou J, Kai Y and Li Y: Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration. Oncotarget. 8:107477–107491. 2017.PubMed/NCBI
16	Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros W, Mueller MD and Yu JJ: Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Rep. 27:286–292. 2012.PubMed/NCBI
17	Zhu H and Yu JJ: Gene expression patterns in the histopathological classification of epithelial ovarian cancer. Exp Ther Med. 1:187–192. 2010. View Article : Google Scholar : PubMed/NCBI
18	Cheng CC, Chou KF, Wu CW, Su NW, Peng CL, Su YW, Chang J, Ho AS, Lin HC, Chen CG, et al: EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. Lung Cancer. 116:80–89. 2018. View Article : Google Scholar : PubMed/NCBI
19	Detterbeck FC, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L, Kennedy C, Krasnik M, Peake M, Rami-Porta R, et al: The IASLC lung cancer staging project: Methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (Eighth) edition of the TNM classification of lung cancer. J Thorac Oncol. 11:1433–1446. 2016. View Article : Google Scholar : PubMed/NCBI
20	Tomczak K, Czerwinska P and Wiznerowicz M: The cancer genome atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
21	Liu K, Wang S, Liu Y, Gu J, Gu S, Xu Z, Zhang R, Wang Z, Ma H, Chen Y and Ji L: Overexpression of MYCN promotes proliferation of non-small cell lung cancer. Tumour Biol. 37:12855–12866. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N and Jiang T: Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 8:e634042013. View Article : Google Scholar : PubMed/NCBI
23	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
24	Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK and Mittendorf EA: Validation study of the American joint committee on cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol. 4:203–209. 2018. View Article : Google Scholar : PubMed/NCBI
25	Duchange N, Pidoux J, Camus E and Sauvaget D: Alternative splicing in the human interleukin enhancer binding factor 3 (ILF3) gene. Gene. 261:345–353. 2000. View Article : Google Scholar : PubMed/NCBI
26	Reichman TW, Parrott AM, Fierro-Monti I, Caron DJ, Kao PN, Lee CG, Li H and Mathews MB: Selective regulation of gene expression by nuclear factor 110, a member of the NF90 family of double-stranded RNA-binding proteins. J Mol Biol. 332:85–98. 2003. View Article : Google Scholar : PubMed/NCBI
27	Chaumet A, Castella S, Gasmi L, Fradin A, Clodic G, Bolbach G, Poulhe R, Denoulet P and Larcher JC: Proteomic analysis of interleukin enhancer binding factor 3 (Ilf3) and nuclear factor 90 (NF90) interactome. Biochimie. 95:1146–1157. 2013. View Article : Google Scholar : PubMed/NCBI
28	Guo C, Xue Y, Yang G, Yin S, Shi W, Cheng Y, Yan X, Fan S, Zhang H and Zeng F: Nanog RNA-binding proteins YBX1 and ILF3 affect pluripotency of embryonic stem cells. Cell Biol Int. 40:847–860. 2016. View Article : Google Scholar : PubMed/NCBI
29	Hinds DA, Buil A, Ziemek D, Martinez-Perez A, Malik R, Folkersen L, Germain M, Malarstig A, Brown A, Soria JM, et al: Genome-Wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis. Hum Mol Genet. 25:1867–1874. 2016. View Article : Google Scholar : PubMed/NCBI
30	Bremer HD, Landegren N, Sjoberg R, Hallgren A, Renneker S, Lattwein E, Leonard D, Eloranta ML, Ronnblom L, Nordmark G, et al: ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease. Sci Rep. 8:48522018. View Article : Google Scholar : PubMed/NCBI
31	Izumi T, Fujii R, Izumi T, Nakazawa M, Yagishita N, Tsuchimochi K, Yamano Y, Sato T, Fujita H, Aratani S, et al: Activation of synoviolin promoter in rheumatoid synovial cells by a novel transcription complex of interleukin enhancer binding factor 3 and GA binding protein alpha. Arthritis Rheum. 60:63–72. 2009. View Article : Google Scholar : PubMed/NCBI
32	Jiang W, Huang H, Ding L, Zhu P, Saiyin H, Ji G, Zuo J, Han D, Pan Y, Ding D, et al: Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 34:4460–4470. 2015. View Article : Google Scholar : PubMed/NCBI
33	Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, et al: Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res. 14:8213–8220. 2008. View Article : Google Scholar : PubMed/NCBI
34	Jiang Z, Slater CM, Zhou Y, Devarajan K, Ruth KJ, Li Y, Cai KQ, Daly M and Chen X: LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis. Breast Cancer Res. 19:622017. View Article : Google Scholar : PubMed/NCBI
35	Ni T, Mao G, Xue Q, Liu Y, Chen B, Cui X, Lv L, Jia L, Wang Y and Ji L: Upregulated expression of ILF2 in non-small cell lung cancer is associated with tumor cell proliferation and poor prognosis. J Mol Histol. 46:325–335. 2015. View Article : Google Scholar : PubMed/NCBI